11/15
10:27 am
bfri
Biofrontera Inc. (NASDAQ: BFRI) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $7.00 price target on the stock.
Low
Report
Biofrontera Inc. (NASDAQ: BFRI) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $7.00 price target on the stock.
11/15
02:22 am
bfri
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ... [Yahoo! Finance]
Low
Report
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ... [Yahoo! Finance]
11/13
05:22 pm
bfri
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/13
05:15 pm
bfri
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
High
Report
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
11/1
12:18 pm
bfri
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 [Yahoo! Finance]
Medium
Report
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 [Yahoo! Finance]
11/1
11:55 am
bfri
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
Low
Report
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
10/31
10:32 am
bfri
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
High
Report
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
10/14
10:30 am
bfri
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Low
Report
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
10/7
08:45 am
bfri
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
Medium
Report
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
9/25
11:09 am
bfri
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference [Yahoo! Finance]
Low
Report
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference [Yahoo! Finance]
9/25
10:45 am
bfri
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
Low
Report
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference